JP2016511751A5 - - Google Patents

Download PDF

Info

Publication number
JP2016511751A5
JP2016511751A5 JP2015555353A JP2015555353A JP2016511751A5 JP 2016511751 A5 JP2016511751 A5 JP 2016511751A5 JP 2015555353 A JP2015555353 A JP 2015555353A JP 2015555353 A JP2015555353 A JP 2015555353A JP 2016511751 A5 JP2016511751 A5 JP 2016511751A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
follistatin
protein
seq
recombinant follistatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015555353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016511751A (ja
JP6475639B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/012996 external-priority patent/WO2014116981A1/en
Publication of JP2016511751A publication Critical patent/JP2016511751A/ja
Publication of JP2016511751A5 publication Critical patent/JP2016511751A5/ja
Application granted granted Critical
Publication of JP6475639B2 publication Critical patent/JP6475639B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015555353A 2013-01-25 2014-01-24 デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン Expired - Fee Related JP6475639B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361756996P 2013-01-25 2013-01-25
US61/756,996 2013-01-25
US201361915733P 2013-12-13 2013-12-13
US61/915,733 2013-12-13
PCT/US2014/012996 WO2014116981A1 (en) 2013-01-25 2014-01-24 Follistatin in treating duchenne muscular dystrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018203613A Division JP2019059730A (ja) 2013-01-25 2018-10-30 デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン

Publications (3)

Publication Number Publication Date
JP2016511751A JP2016511751A (ja) 2016-04-21
JP2016511751A5 true JP2016511751A5 (https=) 2017-02-23
JP6475639B2 JP6475639B2 (ja) 2019-02-27

Family

ID=50159515

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015555353A Expired - Fee Related JP6475639B2 (ja) 2013-01-25 2014-01-24 デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン
JP2018203613A Pending JP2019059730A (ja) 2013-01-25 2018-10-30 デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018203613A Pending JP2019059730A (ja) 2013-01-25 2018-10-30 デュシェンヌ筋ジストロフィーの治療におけるフォリスタチン

Country Status (12)

Country Link
US (2) US9957309B2 (https=)
EP (1) EP2948161B1 (https=)
JP (2) JP6475639B2 (https=)
KR (1) KR102253597B1 (https=)
CN (1) CN104902915B (https=)
AU (2) AU2014209178B2 (https=)
CA (1) CA2898121A1 (https=)
EA (1) EA201590719A1 (https=)
ES (1) ES2715710T3 (https=)
IL (1) IL240024B (https=)
MX (1) MX362105B (https=)
WO (1) WO2014116981A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
AU2009262970A1 (en) 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an activin-ActRIIa antagonist and monitoring of treated patients
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EA201590719A1 (ru) * 2013-01-25 2015-12-30 Шир Хьюман Дженетик Терапис, Инк. Фоллистатин в лечении мышечной дистрофии дюшенна
PT2971039T (pt) 2013-03-14 2020-05-06 Immusoft Corp Métodos para diferenciação e transdução in vitro de células b de memória com vetores virais pseudotipados vsv-g
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
US10023621B2 (en) * 2014-06-04 2018-07-17 Acceleron Pharma Inc. Follistatin-related fusion proteins
AU2016238254B2 (en) * 2015-03-26 2022-05-05 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
CA3010599C (en) * 2016-01-06 2025-05-20 Stealth Biotherapeutics Inc. METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
WO2017152090A2 (en) * 2016-03-04 2017-09-08 Shire Human Genetic Therapies, Inc. Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy
JP2020519291A (ja) * 2017-05-12 2020-07-02 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 組み換えフォリスタチン−fc融合タンパク質およびデュシェンヌ型筋ジストロフィーの治療における使用
KR101822633B1 (ko) * 2017-08-22 2018-01-26 (주)진셀팜 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도
WO2019046903A1 (en) * 2017-09-08 2019-03-14 Baker Heart and Diabetes Institute THERAPEUTIC METHOD FOR INCREASING MUSCLE MASS IN A SUBJECT
CN111936617A (zh) * 2018-03-16 2020-11-13 益缪索夫特公司 经遗传工程化以分泌卵泡抑素的b细胞以及使用所述b细胞来治疗卵泡抑素相关的疾病、病况、病症及增强肌肉生长和力量的方法
WO2019191204A1 (en) * 2018-03-28 2019-10-03 Acceleron Pharma Inc. Follistatin polypeptides for the treatment of muscle contracture
CA3094859A1 (en) * 2020-10-01 2022-04-01 Entos Pharmaceuticals Inc. Proteolipid vesicles formulated with fusion associated small transmembrane proteins
KR102361657B1 (ko) 2021-04-26 2022-02-14 주식회사 케이에스비튜젠 14-디옥시-11,12-디디히드로안드로그라폴라이드 석시네이트를 유효성분으로 함유하는 듀센형 근이영양증을 포함한 유전성 근육질환의 예방 또는 치료용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
BR0307871A (pt) 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
JP4688483B2 (ja) * 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
WO2008030367A2 (en) * 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
JP5773868B2 (ja) * 2008-06-26 2015-09-02 アクセルロン ファーマ, インコーポレイテッド アクチビン−ActRIIaのアンタゴニストおよび赤血球レベルを高めるためのその使用
AU2009262970A1 (en) 2008-06-26 2009-12-30 Acceleron Pharma Inc. Methods for dosing an activin-ActRIIa antagonist and monitoring of treated patients
BR112012005225B8 (pt) * 2009-09-09 2023-01-10 Acceleron Pharma Inc Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
US9023890B2 (en) * 2009-12-02 2015-05-05 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
US8580922B2 (en) * 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
EP2861617A1 (en) 2012-06-15 2015-04-22 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
TWI633117B (zh) 2012-09-13 2018-08-21 必治妥美雅史谷比公司 結合至肌肉生長抑制素(myostatin)以纖維連接蛋白爲主之支架結構域蛋白質
EA201590719A1 (ru) * 2013-01-25 2015-12-30 Шир Хьюман Дженетик Терапис, Инк. Фоллистатин в лечении мышечной дистрофии дюшенна
WO2014187807A1 (en) 2013-05-21 2014-11-27 Arcarios B.V. Follistatin derivatives
US10023621B2 (en) 2014-06-04 2018-07-17 Acceleron Pharma Inc. Follistatin-related fusion proteins
WO2016057975A2 (en) 2014-10-10 2016-04-14 Research Institute At Nationwide Children's Hospital Guided injections for aav gene transfer to muscle

Similar Documents

Publication Publication Date Title
JP2016511751A5 (https=)
JP2025000642A5 (https=)
JP2022502056A5 (https=)
JP2020040969A5 (https=)
JP2015522576A5 (https=)
JP2016538885A5 (https=)
JP2020023567A5 (https=)
JP2016513669A5 (https=)
JP2012529296A5 (https=)
JP2018522563A5 (https=)
JP2010519931A5 (https=)
JP2013512678A5 (https=)
CN108307642B (zh) 改造的白介素12及其在制备治疗肿瘤药物中的用途
MX383971B (es) Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan.
JP2016516016A5 (https=)
CN107847565B (zh) 用于肌肉减少症治疗的包括胰高血糖素样肽-1受体激动剂的药物组合物
JP2011511090A5 (https=)
US20240002462A1 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
JP2019509735A5 (https=)
JP2021531834A5 (https=)
JP2020519291A5 (https=)
JP2019524090A5 (https=)
JP2022546402A (ja) ウイルス感染症を処置するための組成物及び方法
JP2014529399A5 (https=)
JPWO2020206098A5 (https=)